Previous close | 37.07 |
Open | 36.81 |
Bid | 37.32 x 0 |
Ask | 37.62 x 0 |
Day's range | 36.81 - 36.81 |
52-week range | 35.44 - 44.48 |
Volume | |
Avg. volume | 37 |
Market cap | N/A |
Beta (5Y monthly) | N/A |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Venlo, The Netherlands, April 09, 2024 (GLOBE NEWSWIRE) -- QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) announced plans to release results for the first quarter 2024. Press release date / time: Monday, April 29, shortly after 22:05 Frankfurt time / 21:05 London time / 16:05 New York time. Conference call date / time: Tuesday, April 30, at 15:00 Frankfurt time / 14:00 London time / 09:00 New York time. Three options for joining the conference call Register for call back connection - C
QIAGEN's (QGEN) new products, coupled with the IVD version of QIAGEN's digital PCR platform QIAcuity, are planned to be released in mid-2024.
Novel QIAcuity dPCR PanCancer Kits can detect rare mutations of EGFR and BRAF genes at the same time, while saving sample material, reducing time and cost // New QIAseq Targeted RNA-seq Panel for T-cell Receptor allows targeted next-generation sequencing of T-cell receptors, increasing accuracy and sensitivity PAXgene® Urine Liquid Biopsy Set to enable non-invasive sample collection and cell-free DNA stabilization, thereby allowing researchers to make advances in urine liquid biopsyVenlo, the Ne